Lilly's eloralintide plus tirzepatide cuts weight 23.3% in Phase 2b
Tirzepatide 15 mg alone produced 14.8% and eloralintide alone up to 12.3% in the 48-week trial of 367 adults with obesity and type 2 diabetes.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 12 13:05 ETSource: Drug Discovery News
The wire
- 01In the 48-week Phase 2b, top-dose EloraTZP cut body weight 23.3% and A1C 2.9 points, versus 14.8% and 2.4 points on tirzepatide 15 mg; eloralintide 6 mg with tirzepatide 5 mg gave 19.4%.
- 02The result sharpens amylin as the pairing of choice with incretins, after Novo's CagriSema produced 15.7% over 68 weeks in a similar population and filed with the FDA.
- 03Gastrointestinal events were more common on the combination, with 10.8% to 27.0% discontinuing for adverse events versus 2.9% on tirzepatide, and headline figures assume all participants stayed on treatment.
From the source
Read at drugdiscoverynews.comLilly's amylin combo raises the bar, and the stakes, for obesity drug developers
Eli Lilly's latest obesity readout is more than a win for one program. By showing that an amylin agonist added to tirzepatide can push weight loss well past what tirzepatide achieves alone, the company has given drug developers a clearer picture of where the field is heading and what it will take to compete there.
